Loading
Oramed Pharmaceuticals Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 04 Apr 2023.
Oramed Pharmaceuticals Inc.: what insiders have been doing
Headquartered in New York City, United States, Oramed Pharmaceuticals Inc. belongs to the Healthcare & Pharma sector and traces its origins to 2002. Filings by its managers are published through SEC (Form 4). Over the twelve months to 18 October 2026, 33 filings were filed, from 12 insiders.
The flow runs one way only: 2 sales worth €199k, from 2 insiders, and no purchase. The largest single trade was a sale of €119k by Hexter Joshua, published on 2 October 2026, equal to 0.070% of the market capitalisation.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 33 filings, this issuer sits above that mark. Our records for Oramed Pharmaceuticals Inc. go back to 2021, with 4 purchases and 8 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at 64.0 m USD; the dividend was 0.25 USD per share.
Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
126
Thresholds
n/a
Buy Volume
€284,311
4 ops. · all time
Sell Volume
€5M
8 ops. · all time
Who traded when
BuySaleAvraham Gabay1 sale
Joshua Hexter1 sale
Since the insiders bought
- +23.1%Entry US$2.12 · Close at T+365 US$2.61
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 3,702 of 24,148 companies
69.7
score / 100
Value73
Quality67
FCF yld-6.5%
Earn yld37%
EV/EBITDA2.3x
ROE74%
Gross mgn0.7%
Net mgn·
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.27
Analyst consensus
1 analystsUS$7.00Target US$7.00(+64%)US$7.00
Income statement
RevenueUS$2M
Gross profitUS$13k1% margin
EBITDAUS$75.4M3772% margin
Net incomeUS$64.1M3202.5% margin
Valuation
PER (trailing)1.0x
P/Book0.6x
Beta1.28
Balance sheet & cash
Market capUS$174.8M
Total debtUS$825k
Free Cash Flow-US$11.1M
Debt / Equity0%
Profitability & ownership
ROE74.2%
ROA-3.4%
% insiders21.3%
% institutions45.1%
Last declaration on 2 October 2026
Declarations126 total
20,000 shares@ US$4.510.047% mcap16.8% of flowCommon StockSEC:0001213900-26-106531:0
30,000 shares@ US$4.5110.070% mcap17.1% of flowCommon StockSEC:0001213900-26-106530:0
30,000 shares@ US$4.670.072% mcap100.0% of flowCommon StockSEC144:0001976408-26-000876
209,291 sharesCommon StockSEC:0001213900-26-103535:0
75,455 sharesCommon StockSEC:0001213900-26-103538:0
209,291 sharesCommon StockSEC:0001213900-26-103538:1
349,497 sharesCommon StockSEC:0001213900-26-103540:0
368,765 sharesCommon StockSEC:0001213900-26-103540:1
208,125 sharesCommon StockSEC:0001213900-26-103536:0
209,291 sharesCommon StockSEC:0001213900-26-103536:1
93,360 shares@ US$4.810.23% mcap100.0% of flowCommon StockSEC144:0001976408-26-000608
137,000 shares@ US$4.810.34% mcap100.0% of flowCommon StockSEC144:0001976408-26-000609
435,084 shares@ US$3.3187.0% of flowCommon StockSEC:0001213900-26-037446:0
44,818 shares@ US$3.312.9% of flowCommon StockSEC:0001213900-26-037447:0
167,005 shares0Common StockSEC:0001213900-26-031013:0
95,889 shares0Common StockSEC:0001213900-26-031012:0
95,889 shares0Common StockSEC:0001213900-26-031011:0
119,558 shares0Common StockSEC:0001213900-26-031015:0
100,000 shares0Common StockSEC:0001213900-26-028291:0
109,000 shares0Common StockSEC:0001213900-26-009479:0
19,000 shares0Common StockSEC:0001213900-26-009478:0
19,000 shares0Common StockSEC:0001213900-26-009477:0
19,000 shares0Common StockSEC:0001213900-26-009476:0
86,166 shares0Common StockSEC:0001213900-26-006215:0
25 of 126 declarations
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ market (ticker: ORMP), with regulatory references that also reflect its historical international footprint. The company is headquartered in New York, United States, and was established in 2006. Its business model is built around a proprietary oral drug-delivery platform designed to convert therapies that are typically administered by injection into orally deliverable formulations. As a result, Oramed is best viewed as a platform-driven specialty biotech rather than a traditional commercial pharma company.
The company’s core strategic asset is its oral insulin program, developed around its Protein Oral Delivery (POD™) technology. This platform is intended to protect sensitive therapeutic proteins in the digestive tract and enhance absorption so they can be taken by mouth. Oramed’s flagship product candidate, ORMD-0801, has been positioned as an oral insulin capsule for diabetes, especially type 2 diabetes, and has been studied in clinical trials, including trials run in the United States under FDA oversight. Beyond oral insulin, the company has historically explored adjacent applications of the same delivery technology and other pipeline concepts that could broaden the platform’s commercial value.
Read moreShow less
From a competitive standpoint, Oramed occupies a highly specialized niche. It is not competing with large pharmaceutical companies on scale or marketed product breadth; rather, it seeks to differentiate itself through a potentially disruptive administration route. If successful, oral delivery of insulin could improve convenience, patient adherence, and early treatment acceptance versus injections. However, the company also faces the standard biotech risks: clinical uncertainty, regulatory hurdles, manufacturing complexity, and the challenge of translating proof-of-concept into a scalable commercial product.
Recent developments suggest that Oramed has also been managing its balance sheet and strategic optionality actively. In 2025 and early 2026, the company announced transactions and agreements involving Scilex and Lifeward, alongside material cash proceeds from strategic investments. These events strengthened financial flexibility and are among the most important recent corporate milestones. For investors, Oramed should therefore be analyzed as a small-cap healthcare name with meaningful upside optionality, but also a high degree of execution risk tied to clinical progress, partnership strategy, and monetization of its oral-delivery intellectual property.
